| Literature DB >> 36081431 |
Zhuifeng Guo1, Xuwei Lu1, Fan Yang1, Liang Qin1, Ning Yang1, Peiran Cai2, Conghui Han3, Jiawen Wu1, Hang Wang4.
Abstract
Purpose: We aimed to investigate the changes of serum and cell exosome miR-205 levels in patients with prostate carcinoma and its clinical significance. Materials andEntities:
Mesh:
Substances:
Year: 2022 PMID: 36081431 PMCID: PMC9448532 DOI: 10.1155/2022/1784791
Source DB: PubMed Journal: Comput Math Methods Med ISSN: 1748-670X Impact factor: 2.809
The relationship between the expression of exosome miR-205 secreted by serum of prostate cancer patients and clinicopathological features of prostate cancer patients (n = 60).
| Characteristics | miR-205 expression | Chi-squared test |
| |
|---|---|---|---|---|
| Low no. cases | High no. cases | |||
| All patients | ( | ( | ||
| Age(years) | 0.156 | 0.693 | ||
| ≤60 | 13 | 20 | ||
| >60 | 12 | 15 | ||
| Tumor stage | 9.16 | 0.002 | ||
| ≤T2 | 8 | 25 | ||
| >T2 | 17 | 10 | ||
| Lymph node metastasis | 5.173 | 0.023 | ||
| Negative | 9 | 23 | ||
| Positive | 16 | 12 | ||
| Distant metastasis | 7.837 | 0.005 | ||
| M0 | 8 | 24 | ||
| M1 | 17 | 11 | ||
| PSA at initial diagnosis (ng/mL) | 11.051 | 0.001 | ||
| ≤20 | 7 | 25 | ||
| >20 | 18 | 10 | ||
Figure 1The miR-205 expression in the database. (a) The miR-205 expression in prostate tumor tissues and normal tissues. (b) The relationship between the expression of miR-205 expression and age in prostate cancer tissues. (c) The relationship between miR-205 expression and lymph node metastasis in prostate cancer tissues. (d) The relationship between miR-205 expression and Gleason score in prostate cancer tissues.
Figure 2The miR-205 expression in exosomes extracted from prostate carcinoma cell lines and the biological function. (a) The miR-205 expression in exosomes extracted from prostate carcinoma cell lines and normal prostatic cell line of epithelium. (b) The miR-205 expression in exosomes extracted from miR-NC group and miR-205 mimics. (c) The miR-205 promotes the proliferation of prostate cancer cells. (d) The miR-205 promotes the migration of prostate cancer cells. ∗P < 0.05, ∗∗P < 0.01, and ∗∗∗P < 0.001 (Student's t-test). Abbreviations: HR: hazard ratio; CI: confidence interval.
Figure 3The relationship between the expression level of serum exosome-mediated miR-205 and pathological, clinical features in prostate cancer patients. (a) The miR-205 expression in serum exosomes of people with prostate tumor and healthy patients. (b) The miR-205 expression was divided into high (above the mean, n = 35) and low (below the mean, n = 25) miR-205 expression classes. (c) The relationship between the expression level of serum exosome-mediated miR-205 and carcinoma stage, lymph node metastasis in prostate carcinoma. (d) The relationship between the expression level of serum exosome-mediated miR-205 and distant metastasis, PSA level in prostate carcinoma at initial diagnosis. ∗P < 0.05, ∗∗P < 0.01, and ∗∗∗P < 0.001 (Student's t-test).
Univariate and multivariate analysis of overall survival in patients with prostate cancer (n = 60).
| Variable for overall survival | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI |
| HR | 95% CI |
| |
| Age(years) | 0.897 | |||||
| ≤60 vs. >60 | 1.043 | 0.547-1.989 | ||||
| Lymph node metastasis | 0.071 | |||||
| Negative vs. positive | 1.819 | 0.950-3.485 | ||||
| Distant metastasis | 0.218 | |||||
| M0 vs. M1 | 1.501 | 0.786-2.863 | ||||
| Tumor stage | 0.011 | 0.105 | ||||
| ≤T2 vs. >T2 | 2.364 | 1.220-4.580 | 0.565 | 0.283-1.128 | ||
| PSA at initial diagnosis (ng/mL) | 0.008 | 0.294 | ||||
| ≤20 vs. >20 | 2.45 | 1.263-4.754 | 0.671 | 0.318-1.414 | ||
| miR-205 expression |
| 0.021 | ||||
| Low vs. high | 3.251 | 1.675-6.313 | 0.417 | 0.198-0.878 | ||
Figure 4The relationship between miR-205 expression in serum exosomes of people with prostate cancer and prognosis of patients.